Who is sponsoring NCT07527182?

NCT07527182 is sponsored by Didier Menard.

What drugs are being tested in NCT07527182?

Interventions in NCT07527182: Artemether-Lumefantrine Tab 20-120mg.

What condition does NCT07527182 study?

NCT07527182 studies Malaria (Plasmodium Falciparum), Drug Resistance, Artemisinin-resistant, Ethiopia.

Is NCT07527182 still recruiting?

NCT07527182 is currently completed. Last updated 14 April 2026.

Last reviewed 2026-04-14 · How we verify

NCT07527182: ETH-ART-R

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Artemisinin Partial Resistance in Ethiopian Plasmodium Falciparum: A Multisite Clinical, Molecular and In Vitro Study

Completed NA Last updated 14 April 2026

What this trial tests

NA trial testing Artemether-Lumefantrine Tab 20-120mg in Malaria (Plasmodium Falciparum) in 277 participants. Completed in 7 April 2026.

Timeline

1 May 2024

Primary endpoint
30 October 2025

7 April 2026

Quick facts

Lead sponsor	Didier Menard
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	277
Start date	1 May 2024
Primary completion	30 October 2025
Estimated completion	7 April 2026
Sites	5 locations across Ethiopia

Drugs / interventions tested

Artemether-Lumefantrine Tab 20-120mg — full drug profile →

Conditions studied

Malaria (Plasmodium Falciparum) — all drugs for Malaria (Plasmodium Falciparum) →
Drug Resistance — all drugs for Drug Resistance →
Artemisinin-resistant — all drugs for Artemisinin-resistant →
Ethiopia — all drugs for Ethiopia →

Sponsor

Didier Menard

Who can join

6 Months and older, any sex, with Malaria (Plasmodium Falciparum) or Drug Resistance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Artemisinin-based combination therapies (ACTs) are the main treatment for falciparum malaria in Africa. Artemisinin partial resistance (ART-R), characterized by delayed parasite clearance after treatment, has been confirmed in four sub-Saharan African countries. In Ethiopia, molecular surveys have detected the Pfkelch13 R622I mutation associated with ART-R at multiple sites, but no study has yet combined clinical, molecular, and in vitro evidence to confirm ART-R per WHO criteria. This multisite study conducted across five sentinel sites in Ethiopia (2024-2025) assessed day-3 parasite positivity after artemether-lumefantrine treatment, Pfkelch13 genotyping, and ring-stage survival assay on culture-adapted field isolates, to determine whether ART-R is confirmed in Ethiopian Plasmodium falciparum populations.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Artemether-Lumefantrine Tab 20-120mg

Trials testing the same drug.

NCT03241901 — "Prolonging the Therapeutic Life Span of Artemisinin-based Combination Therapies (ACT) in Bagamoyo District, Tanzania" · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07527182 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Didier Menard
Last refreshed: 14 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07527182.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing